Objective: To test whether sugammadex, a reversal agent for steroid neuromuscular blocking drugs, could encapsulate the neurosteroid alfaxalone and accelerate anesthetic recovery.
Study design: Prospective, blinded, randomized, crossover study.
Animals: Thirty-six male and female adult Sprague-Dawley rats.
Methods: Six male and six female adult Sprague-Dawley rats were intravenously administered 3 mg kg-1 alfaxalone followed 1 minute later by either 0.9% saline or 96 mg kg-1 sugammadex, with a 1 week washout period between repeat anesthetics. A separate cohort of 12 rats was studied using an identical experimental design, but with a 6 mg kg-1 alfaxalone dose. A third cohort of 12 rats was given 12 mg kg-1 alfaxalone followed by saline or sugammadex (96 mg kg-1 dose or 192 mg kg-1 dose) using a Latin-square crossover design with 1 week between repeated anesthetics. Physiological and behavioral recovery responses were assessed every minute by an observer who was blinded to treatment. Data were analyzed using repeated-measures ANOVA with Šidák post hoc comparisons (p < 0.05).
Results: Compared with saline controls, sugammadex shortened recovery times by 40-60% following anesthesia induction with the 3 or 6 mg kg-1 alfaxalone doses (p ≤ 0.002). For the 12 mg kg-1 alfaxalone dose, the low and the high sugammadex doses shortened recovery times by 25-50% and 50-61%, respectively, compared with saline controls, with all differences being significant (p ≤ 0.003) except for movement following tail clamp (p = 0.112-0.419). This higher sugammadex dose also shortened the same significant recovery end points compared with the lower sugammadex dose (p = 0.007-0.050). At higher alfaxalone doses, female rats exhibited significantly slower recoveries than male rats.
Conclusions and clinical relevance: Sugammadex can be used to reverse anesthetic effects from alfaxalone in rats. Recovery speed from alfaxalone anesthesia is dependent on sugammadex dose and sex.
扫码关注我们
求助内容:
应助结果提醒方式:
